AzTrials
AzTrials

Intestinal Anastomotic LeakNCT04604964

Risk Factors for Anatomic Leakage in Advanced Ovarian Cancer Surgery

An observational study of Intestinal Anastomotic Leak, run by Catholic University of the Sacred Heart at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cytoreductive surgery is currently the main treatment for advanced epithelial ovarian cancer (AEOC), and the complete disease removal (RT=0) or the achievement of an optimal residual disease (RT < 1 cm) remain the factors with the greatest prognostic impact, both in primary debulking surgery (PDS) and interval… Read more about this study

Who is it for?
Any age, women only
Conditions the study is for
Intestinal Anastomotic Leak
What is being tested?
Evaluation of anastomotic leakage occurrence
How many people
515 participants
Where
1 siteItaly
Study dates
Dec 2011to Sep 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients with histological diagnosis of epithelial ovarian, fallopian or peritoneal cancer (FIGO stage IIB-IVB), judged suitable for surgery by clinicians, and who underwent recto-sigmoid resection and anastomosis with curative intent between December 2011 and October 2019

Who may be able to join

  • histological diagnosis of epithelial ovarian, fallopian or peritoneal cancer
  • FIGO stage IIB-IVB
  • patients judged suitable for surgery by clinicians
  • patients subjected to recto-sigmoid resection and anastomosis with curative intent

Who cannot join

  • Patients with no evidence of colorectal involvement and did not undergo recto-sigmoid resection
  • patients with end-colostomy or end-ileostomy

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Fondazione Policlinico Universitario A. Gemelli, IRCCS

    Rome, RM, 00168

Other trials in Italy

About this study

Official title: Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery: A Large Single Centre Experience

Cytoreductive surgery is currently the main treatment for advanced epithelial ovarian cancer (AEOC), and the complete disease removal (RT=0) or the achievement of an optimal residual disease (RT < 1 cm) remain the factors with the greatest prognostic impact, both in primary debulking surgery (PDS) and interval debulking surgery (IDS).

To achieve the no residual disease (RT=0), several surgical manoeuvres are often needed both at the upper and lower abdomen, including intestinal resections.

Read more

Recto-sigmoid resection is certainly the most frequent of intestinal resections, and it is also the one with the highest risk of complication.

Albeit rare, anastomosis leakage (AL) is a life-threating condition and therefore it is the most feared of intestinal complications.

The aim of this large single-center retrospective study was to assess the AL rate in patients subjected to colorectal resection and anastomosis during primary surgery (PDS or IDS) for advanced ovarian cancer, in a third referral centre for gynecologic oncology with ESGO certification.

In addition, we evaluated several possible pre/intra and post-operative risk factors for AL in order to identify, at an early stage, the population at greatest risk, and attempt to reduce the morbidity and mortality of this severe post-operative complication

Read the detailed description

The investigators performed a retrospective analysis of the pre-operative, intra-operative and post-operative (surgical outcomes and early complications rate) characteristics, of a series of patients undergoing primary surgery (PDS or IDS) for AEOC at"Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Department of Gynecologic Oncology" between December 2011 and October 2019.

The enrolled population included all patients with histological diagnosis of epithelial ovarian, fallopian or peritoneal cancer (FIGO stage IIB-IVB), judged suitable for surgery by clinicians, and who underwent recto-sigmoid resection and anastomosis with curative intent.

Patients with no evidence of colorectal involvement, and who therefore did not undergo recto-sigmoid resection, or patients with end-colostomy or end-ileostomy were excluded from the study.

Pre-operative clinical variables, surgical features and post-operative outcomes were retrospectively retrieved.

Several system scores, helpful in predicting operative risk, were used to classify patients' physiological status, as the American Society of Anesthesiologists (ASA) score, the Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) and the Age-Adjusted Charlson Comorbidity Index (ACCI).

Patients with an ASA score > 2, ECOG-PS >/= 2 and an ACCI > 2 were considered at high risk of post-operative complications.

Pre-operative albumin level below 30 mg/dl and pre-operative hemoglobin values below 10.0 g/dl were indicative respectively of a severely poor nutritional status and moderate-severe anemia.

Other demographic and surgical variables were recorded: age (< 60 vs >/= 60 year-old), body mass index (BMI) (divided into the following categories: underweight patients: BMI <18, normal weight-overweight: BMI 18-30 and obese patients with BMI >/= 30), International Federation of Gynecology and Obstetrics (FIGO) stage (FIGO stage 2014: </= IIIA vs IIIC-IVB), smoking habit, Ca-125 tumor marker level at initial diagnosis (< 1000 U/mL vs >/= 1000 U/mL), surgical timing (PDS vs IDS), Predictive Index Value (PIV) at initial diagnosis (</= 6 vs > 6), presence of ascites (< 500 mL vs >/= 500 mL), Surgical Complexity Score (SCS) (SCS 1-2 vs SCS 3), estimated blood loss (EBL) (EBL < 500 vs >/= 500 mL) , intra-operative transfusions, additional surgical procedures performed and colorectal resection and anastomosis specific characteristics. The Common Terminology Criteria for Adverse Events v3.0 (CTCAE) was used to classify intra-operative complications (CTCAE 0-1 vs CTCAE >/= 2).

The suspicion of anastomotic leakage (AL), suggested by general clinical signs as abdominal pain or distension, leukocytosis, fever, as well as more specific signs such as emission of gas, pus, or feces via the drains, the laparotomy incision, or the vagina, was ascertained by computed tomography (CT) with rectal contrast enema or simple contrast enema radiography with a water-soluble contrast agent.

The ultimate diagnostic procedure was re-laparotomy with direct verification of AL and/or fecal peritonitis.

Overall survival (OS) was calculated from the date of primary diagnosis to the date of death or to last follow-up visit for the patients still alive.

The primary end-point of the study was to assess the anastomosis leakage rate in patients subjected to colorectal resection and anastomosis during primary surgery (PDS or IDS) for advanced ovarian cancer, in a third referral centre for gynecologic oncology with ESGO certification.

The secondary endpoints were to evaluate the influence of several possible pre/intra and post-operative risk factors on AL in order to identify, at an early stage, the population at greatest risk.

Being tested
Evaluation of anastomotic leakage occurrence
Keywords
Recto-sigmoid resection, Advanced Ovarian Cancer, Anastomotic leakage
Medical subject headings
Anastomotic Leak

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Evaluation of anastomotic leakage occurrenceOther

    Anastomotic leakage was defined as the communication between the intra and extraluminal compartments due to a defect in the integrity of the intestinal wall originating from the staple line of the neo-rectal reservoir between the colon and rectum

Study groups in NCT04604964
Study groupRoleWhat they receive
Patients undergoing recto-sigmoid resection plus anastomosisPatients undergoing recto-sigmoid resection and concurrent anastomosis during debulking surgery (primary or interval debunking surgery) for advanced epithelial ovarian cancer.
Receives: Other: Evaluation of anastomotic leakage occurrence

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Anastomotic leakage

    To assess the anastomotic leakage rate in patients subjected to recto-sigmoid resection during debulking surgery for ovarian cancer

    Measured: up to 30 days after surgery

Secondary outcomes (3)
  1. Pre-operative risk factors for anastomotic leakage

    Evaluate the correlation between pre-operative features (age, BMI, ECOG, ACCI, ASA, albumin level, FIGO stage, surgical timing -PDS or IDS, presence of ascites) and the occurrence of anastomotic leakage

    Measured: just before surgery

  2. Intra-operative risk factors for anastomotic leakage

    To evaluate the correlation between surgical procedures (number of bowel resections, hepatic resection, splenectomy, lymphadenectomy, urological procedures as ureteral preimplantation or partial bladder resection, level of inferior mesenteric artery section, distance of the anastomosis from the anal verge, estimated blood loss, intra-operative transfusion, operative time and residual disease) and the occurrence of anastomotic leakage

    Measured: During surgery

  3. Post-operative risk factors for anastomotic leakage

    To evaluate the correlation between early post-operative complications (post-operative anemia and the occurrence of pancreatic fistula) and the occurrence of anastomotic leakage

    Measured: up to 30 days after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Oct 2020
  2. Study startDec 2011
  3. Primary completionOct 2019
  4. Study completionSep 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
515 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04604964
Sponsor's protocol ID
DIPUSVSP-03-02-2032
Status last verified
Oct 2020
First submitted
11 Oct 2020
Last updated
27 Oct 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Intestinal Anastomotic Leak, run by Catholic University of the Sacred Heart at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Anastomotic leakage (time frame: up to 30 days after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in